help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2007-0684
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hess, O.
Right arrow Articles by Tenenbaum-Rakover, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hess, O.
Right arrow Articles by Tenenbaum-Rakover, Y.
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Pediatric Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 11 4387-4393
Copyright © 2007 by The Endocrine Society

Variable Phenotypes in Familial Isolated Growth Hormone Deficiency Caused by a G6664A Mutation in the GH-1 Gene

Ora Hess1, Yasir Hujeirat1, Michael P. Wajnrajch, Stavit Allon-Shalev, Zvi Zadik, Idit Lavi and Yardena Tenenbaum-Rakover

Faculty of Sciences (O.H.), Bar Ilan University, Ramat Gan 52900, Israel; Genetic Institute (O.H., Y.H., S.A.-S.), and Pediatric Endocrine Unit (Y.T.-R.), Ha’ Emek Medical Center, 18101 Afula, Israel; Pfizer Inc. (M.P.W.), New York, New York 10017; Technion Faculty of Medicine (S.A.-S., Y.T.-R.), Haifa 31096, Israel; Pediatric Endocrine Unit (Z.Z.), Kaplan Medical Center, Rehovot and the Hebrew University of Jerusalem, Jerusalem, 76100, Israel; and Department of Community Health and Epidemiology (I.L.), Carmel Medical Center, Haifa 34362, Israel

Address all correspondence and requests for reprints to: Yardena Tenenbaum-Rakover, Director, Pediatric Endocrine Unit, Ha’ Emek Medical Center, Afula 18101, Israel. E-mail: rakover_y{at}clalit.org.il.

Context: G to A transition at position 6664 (G6664A) in human GH-1 results in the substitution of arginine by histidine at position 183 (R183H) of the GH molecule and causes familial isolated GH deficiency type II (IGHD II).

Objectives: The objective of the study was to assess the phenotype-genotype correlation of subjects affected with IGHD II caused by a G6664A mutation in 34 affected members of two large families.

Design and Patients: Sixty-six subjects from two core families were included. The G6664A mutation among family members was determined by restriction fragment length polymorphism.

Results: Twenty-four of the 52 members from family 1 and 10 of 14 from family 2 carried the same G6664A mutation in a heterozygous state. The affected subjects in family 1 were significantly shorter [–2.6 vs. –0.1 SD score (SDS), P < 0.0001] and had significantly lower IGF-I serum levels (–1.9 vs. –0.5 SDS, P < 0.0001), compared with normal-genotype family members. The affected adults exhibited great variability in their stature, ranging from –4.5 to –1.0 (mean –2.8 SDS), with five members being of normal height (>–2 SDS). Twelve children were diagnosed with IGHD. Two affected children had normal peak GH levels, although one of these subsequently demonstrated GH insufficiency (6.5 and 3.7 ng/ml). The affected children from both families exhibited large variability in their height, growth velocity, delay in bone age (chronological age – bone age), age at diagnosis, peak GH response, and IGF-I levels.

Conclusions: These detailed phenotypic analyses show the variable expressivity of patients bearing a G6664A mutation, reflecting the spectrum of GH deficiency in affected patients, even within families, and the presence of additional genes modifying height determination. Our findings raise a new dilemma in the guidelines for the diagnosis of GH deficiency and the indications for GH therapy.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
K. S. Alatzoglou, J. P. Turton, D. Kelberman, P. E. Clayton, A. Mehta, C. Buchanan, S. Aylwin, E. C. Crowne, H. T. Christesen, N. T. Hertel, et al.
Expanding the Spectrum of Mutations in GH1 and GHRHR: Genetic Screening in a Large Cohort of Patients with Congenital Isolated Growth Hormone Deficiency
J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3191 - 3199.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society